In the second study,2 Prof. Xu and colleagues report long-term (median 21 months) of safety and efficacy of therapy of combined anti-B-cell maturation antigen (BCMA) and anti-CD-19 CAR-T-cells in 62 evaluable subjects with advanced PCM. The gene discussed is TNFRSF17; the disease is paracoccidioidomycosis.